A citation-based method for searching scientific literature

Frederique Penault-Llorca, Catherine Abrial, Ines Raoelfils, Anne Cayre, Marie-Ange Mouret-Reynier, Marianne Leheurteur, Xavier Durando, Jean-Louis Achard, Pierre Gimbergues, Philippe Chollet. Hum Pathol 2008
Times Cited: 47







List of co-cited articles
282 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
53

Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome.
D M Sataloff, B A Mason, A J Prestipino, U L Seinige, C P Lieber, Z Baloch. J Am Coll Surg 1995
336
44

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
Keith N Ogston, Iain D Miller, Simon Payne, Andrew W Hutcheon, Tarun K Sarkar, Ian Smith, A Schofield, Steven D Heys. Breast 2003
521
40

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
W Fraser Symmans, Florentia Peintinger, Christos Hatzis, Radhika Rajan, Henry Kuerer, Vicente Valero, Lina Assad, Anna Poniecka, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2007
869
40

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
38


Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, Harry D Bear, Charles E Geyer, Morton S Kahlenberg, André Robidoux, Richard G Margolese, James L Hoehn, Victor G Vogel, Shaker R Dakhil,[...]. J Clin Oncol 2008
29

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
Chafika Mazouni, Florentia Peintinger, Shu Wan-Kau, Fabrice Andre, Ana M Gonzalez-Angulo, W Fraser Symmans, Funda Meric-Bernstam, Vicente Valero, Gabriel N Hortobagyi, Lajos Pusztai. J Clin Oncol 2007
192
27


Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
Davide Mauri, Nicholas Pavlidis, John P A Ioannidis. J Natl Cancer Inst 2005
771
21

Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer.
Manfred Kaufmann, Gunter von Minckwitz, Elefhterios P Mamounas, David Cameron, Lisa A Carey, Massimo Cristofanilli, Carsten Denkert, Wolfgang Eiermann, Michael Gnant, Jay R Harris,[...]. Ann Surg Oncol 2012
311
21

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
H M Kuerer, L A Newman, T L Smith, F C Ames, K K Hunt, K Dhingra, R L Theriault, G Singh, S M Binkley, N Sneige,[...]. J Clin Oncol 1999
21

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Valentina Guarneri, Kristine Broglio, Shu-Wan Kau, Massimo Cristofanilli, Aman U Buzdar, Vicente Valero, Thomas Buchholz, Funda Meric, Lavinia Middleton, Gabriel N Hortobagyi,[...]. J Clin Oncol 2006
433
19

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, E R Fisher, D L Wickerham, M Begovic, A DeCillis, A Robidoux,[...]. J Clin Oncol 1998
19

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
19

Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
Edwin R Fisher, Jiping Wang, John Bryant, Bernard Fisher, Eletherios Mamounas, Norman Wolmark. Cancer 2002
281
19

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Roy E Smith, Charles E Geyer, Eleftherios P Mamounas, Bernard Fisher, Ann M Brown, Andre Robidoux, Richard Margolese, Morton S Kahlenberg,[...]. J Clin Oncol 2006
667
17


Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im,[...]. Lancet Oncol 2012
17


High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer.
Sophie Catherine Abrial, Frédérique Penault-Llorca, Rémi Delva, Philippe Bougnoux, Bernard Leduc, Marie-Ange Mouret-Reynier, Dominique Mery-Mignard, Jean-Pierre Bleuse, Jacques Dauplat, Hervé Curé,[...]. Breast Cancer Res Treat 2005
78
17

Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
Bryan T Hennessy, Gabriel N Hortobagyi, Roman Rouzier, Henry Kuerer, Nour Sneige, Aman U Buzdar, Shu Wan Kau, Bruno Fornage, Aysegul Sahin, Kristine Broglio,[...]. J Clin Oncol 2005
287
14

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L Graham, Charles M Perou. Clin Cancer Res 2007
14

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser,[...]. Lancet 2010
801
14

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
Rohit Bhargava, Sushil Beriwal, David J Dabbs, Umut Ozbek, Atilla Soran, Ronald R Johnson, Adam M Brufsky, Barry C Lembersky, Gretchen M Ahrendt. Cancer 2010
107
14

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
Julie R Gralow, Harold J Burstein, William Wood, Gabriel N Hortobagyi, Luca Gianni, Gunter von Minckwitz, Aman U Buzdar, Ian E Smith, William F Symmans, Baljit Singh,[...]. J Clin Oncol 2008
268
12


The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Ann Brown, Roy Smith, Eleftherios P Mamounas, Bernard Fisher, Richard Margolese, Heather Theoret, Atilla Soran, D Lawrence Wickerham,[...]. J Clin Oncol 2003
793
12

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Marco Colleoni, Giuseppe Viale, David Zahrieh, Giancarlo Pruneri, Oreste Gentilini, Paolo Veronesi, Richard D Gelber, Giuseppe Curigliano, Rosalba Torrisi, Alberto Luini,[...]. Clin Cancer Res 2004
260
12

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Aman U Buzdar, Nuhad K Ibrahim, Deborah Francis, Daniel J Booser, Eva S Thomas, Richard L Theriault, Lajos Pusztai, Marjorie C Green, Banu K Arun, Sharon H Giordano,[...]. J Clin Oncol 2005
822
12

Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer?
P Chollet, S Amat, E Belembaogo, H Curé, M de Latour, J Dauplat, G Le Bouëdec, M-A Mouret-Reynier, J-P Ferrière, F Penault-Llorca. Br J Cancer 2003
32
18

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.
Ian C Smith, Steven D Heys, Andrew W Hutcheon, Iain D Miller, Simon Payne, Fiona J Gilbert, Antoinne K Ah-See, Oleg Eremin, Leslie G Walker, Tarun K Sarkar,[...]. J Clin Oncol 2002
550
12

Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.
Roman Rouzier, Jean-Marc Extra, Jerzy Klijanienko, Marie-Christine Falcou, Bernard Asselain, Anne Vincent-Salomon, Philippe Vielh, Edwige Bourstyn. J Clin Oncol 2002
240
12

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Michael Untch, Peter A Fasching, Gottfried E Konecny, Stephan Hasmüller, Annette Lebeau, Rolf Kreienberg, Oumar Camara, Volkmar Müller, Andreas du Bois, Thorsten Kühn,[...]. J Clin Oncol 2011
358
12

Preoperative chemotherapy for women with operable breast cancer.
J S D Mieog, J A van der Hage, C J H van de Velde. Cochrane Database Syst Rev 2007
241
12

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
Judith Hurley, Philomena Doliny, Isildinha Reis, Orlando Silva, Carmen Gomez-Fernandez, Pedro Velez, Giovanni Pauletti, Jodeen E Powell, Mark D Pegram, Dennis J Slamon. J Clin Oncol 2006
175
12

A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN).
Philippe Chollet, Catherine Abrial, Xavier Durando, Emilie Thivat, Olivier Tacca, Marie-Ange Mouret-Reynier, Marianne Leheurteur, Fabrice Kwiatkowski, Jacques Dauplat, Frédérique Penault-Llorca. Cancer J 2008
28
21

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim,[...]. N Engl J Med 2017
705
12


American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
Lisa A Carey, Richard Metzger, E Claire Dees, Frances Collichio, Carolyn I Sartor, David W Ollila, Nancy Klauber-DeMore, Jan Halle, Lynda Sawyer, Dominic T Moore,[...]. J Natl Cancer Inst 2005
137
10

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
S Dawood, S D Merajver, P Viens, P B Vermeulen, S M Swain, T A Buchholz, L Y Dirix, P H Levine, A Lucci, S Krishnamurthy,[...]. Ann Oncol 2011
303
10

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma.
R L Jones, S R Lakhani, A E Ring, S Ashley, G Walsh, I E Smith. Br J Cancer 2006
75
10

Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
Elizabeth A Mittendorf, Yun Wu, Maurizio Scaltriti, Funda Meric-Bernstam, Kelly K Hunt, Shaheenah Dawood, Francisco J Esteva, Aman U Buzdar, Huiqin Chen, Sameena Eksambi,[...]. Clin Cancer Res 2009
214
10

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Michael Untch, Mahdi Rezai, Sibylle Loibl, Peter A Fasching, Jens Huober, Hans Tesch, Ingo Bauerfeind, Jörn Hilfrich, Holger Eidtmann, Bernd Gerber,[...]. J Clin Oncol 2010
369
10


Comparison among different classification systems regarding the pathological response of preoperative chemotherapy in relation to the long-term outcome.
Tadahiko Shien, Chikako Shimizu, Kunihiko Seki, Taro Shibata, Takashi Hojo, Masashi Ando, Tsutomu Kohno, Noriyuki Katsumata, Sadako Akashi-Tanaka, Takayuki Kinoshita,[...]. Breast Cancer Res Treat 2009
16
31

Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
Nehmat Houssami, Petra Macaskill, Gunter von Minckwitz, Michael L Marinovich, Eleftherios Mamounas. Eur J Cancer 2012
301
10

Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer.
T Hirata, C Shimizu, K Yonemori, A Hirakawa, T Kouno, K Tamura, M Ando, N Katsumata, Y Fujiwara. Br J Cancer 2009
65
10

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013
10

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.